Sivik Global Healthcare LLC Cuts Stock Position in Abbott Laboratories $ABT

Sivik Global Healthcare LLC lessened its stake in Abbott Laboratories (NYSE:ABT) by 12.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 39,200 shares of the healthcare product maker’s stock after selling 5,800 shares during the quarter. Abbott Laboratories accounts for 1.5% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 19th biggest holding. Sivik Global Healthcare LLC’s holdings in Abbott Laboratories were worth $5,332,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ABT. Brighton Jones LLC grew its stake in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Abbott Laboratories by 17.0% during the first quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock valued at $5,103,000 after acquiring an additional 5,590 shares in the last quarter. West Branch Capital LLC raised its position in shares of Abbott Laboratories by 13.3% in the 1st quarter. West Branch Capital LLC now owns 17,677 shares of the healthcare product maker’s stock valued at $2,345,000 after purchasing an additional 2,080 shares during the last quarter. CVA Family Office LLC raised its position in shares of Abbott Laboratories by 2.5% in the 1st quarter. CVA Family Office LLC now owns 7,555 shares of the healthcare product maker’s stock valued at $1,002,000 after purchasing an additional 183 shares during the last quarter. Finally, Goldstone Financial Group LLC raised its position in shares of Abbott Laboratories by 39.8% in the 1st quarter. Goldstone Financial Group LLC now owns 13,901 shares of the healthcare product maker’s stock valued at $1,844,000 after purchasing an additional 3,954 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.8%

Abbott Laboratories stock opened at $132.30 on Friday. The stock has a 50-day moving average price of $132.54 and a 200 day moving average price of $131.60. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $230.26 billion, a price-to-earnings ratio of 16.58, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the business earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Wall Street Analysts Forecast Growth

ABT has been the subject of several research analyst reports. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and increased their price objective for the company from $143.00 to $145.00 in a research report on Friday, July 18th. The Goldman Sachs Group increased their price objective on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Evercore ISI increased their price objective on shares of Abbott Laboratories from $140.00 to $144.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Finally, Mizuho lifted their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $146.17.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.